Thermo Fisher Scientific Inc. $TMO is Scientech Research LLC's 6th Largest Position

Key Points

• Scientech Research LLC increased its stake in Thermo Fisher Scientific by 87.4% in Q1, acquiring 2,389 additional shares, bringing its total to 5,122 shares valued at approximately $2.55 million.
• The recent quarterly earnings report showed Thermo Fisher achieved $10.86 billion in revenue, exceeding estimates of $10.68 billion, with an earnings per share (EPS) of $5.36.
• In executive transactions, CEO Marc N. Casper sold 10,000 shares, reflecting a 7.99% decrease in his holdings, while EVP Gianluca Pettiti sold 400 shares, resulting in a 1.76% decrease of his position.

Scientech Research LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 87.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,122 shares of the medical research company's stock after purchasing an additional 2,389 shares during the period. Thermo Fisher Scientific comprises approximately 0.7% of Scientech Research LLC's investment portfolio, making the stock its 6th largest position. Scientech Research LLC's holdings in Thermo Fisher Scientific were worth $2,549,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. Port Capital LLC boosted its holdings in Thermo Fisher Scientific by 1.6% in the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after acquiring an additional 22 shares in the last quarter. Clark Capital Management Group Inc. increased its holdings in Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after purchasing an additional 23 shares in the last quarter. Monograph Wealth Advisors LLC lifted its holdings in Thermo Fisher Scientific by 0.3% during the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after acquiring an additional 23 shares during the period. Finally, Intergy Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock valued at $208,000 after acquiring an additional 23 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMO. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, September 7th. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. Barclays raised Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $490.00 to $550.00 in a report on Thursday. Finally, Evercore ISI reduced their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $592.24.

Insider Activity

In related news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.6%

Shares of NYSE:TMO traded down $7.98 during trading on Friday, reaching $483.43. 570,901 shares of the company were exchanged, compared to its average volume of 2,393,154. The business's fifty day simple moving average is $465.84 and its 200-day simple moving average is $452.06. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The firm has a market capitalization of $182.55 billion, a PE ratio of 27.97, a P/E/G ratio of 2.54 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.